Physician profile
Jamil Ibrahim
NPI 1306267745
$5,114.51
in general payments reported to CMS, 2019-2025
18 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $21.96 · 2021: $1,131 · 2022: $926 · 2023: $2,327 · 2024: $462 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494 · Travel and Lodging: $514 · Education: $27.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.36 |
| Travel and Lodging | $514.22 |
| Education | $27.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $931.46 | 2022-2023 | Ellipsys Vascular Access System |
| Novo Nordisk INC | $761.74 | 2021-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $719.03 | 2020-2024 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $415.50 | 2022-2025 | Veltassa |
| Amgen INC. | $386.73 | 2021-2024 | Evenity, Tavneos, Parsabiv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.74 | 2022-2023 | Ofev |
| Aurinia Pharma U.S., INC. | $356.83 | 2021-2023 | Lupkynis |
| Genzyme Corporation | $268.92 | 2023 | |
| Baxter Healthcare | $136.59 | 2023 | |
| Abbvie INC. | $125.00 | 2025 | |
| Glaxosmithkline, LLC. | $125.00 | 2024 | Arexvy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.58 | 2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $107.88 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $106.05 | 2022 | |
| Travere Therapeutics, INC. | $86.64 | 2023-2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $47.46 | 2023 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $25.07 | 2023 | Jynarque |
| Calliditas Therapeutics US INC. | $22.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamil Ibrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.